{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:51:17Z","timestamp":1792464677194,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","thrombosisresearch.com","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.thromres.2025.109306","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T16:09:00Z","timestamp":1741968540000},"page":"109306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["FVIII half-life products: A real-world experience"],"prefix":"10.1016","volume":"249","author":[{"given":"Ezio","family":"Zanon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Porreca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Simion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Simioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2025.109306_bb0005","series-title":"GeneReviews\u00ae","article-title":"Hemophilia A","author":"Konkle","year":"1993"},{"issue":"5","key":"10.1016\/j.thromres.2025.109306_bb0010","first-page":"378","article-title":"Intracranial haemorrhage in children and adults with haemophilia A and B: a literature review of the last 20 years","volume":"17","author":"Zanon","year":"2019","journal-title":"Blood Transfus."},{"key":"10.1016\/j.thromres.2025.109306_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.thromres.2025.109306_bb0020","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.thromres.2025.109306_bb0025","first-page":"8","article-title":"Determination of pharmacokinetics of replacement factor VIII","volume":"27","author":"Mannucci","year":"1990","journal-title":"Semin. Hematol."},{"issue":"9","key":"10.1016\/j.thromres.2025.109306_bb0030","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00228-009-0676-x","article-title":"Pharmacokinetics and dose requirements of factor VIII over the age range 3\u201374 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A","volume":"65","author":"Bj\u00f6rkman","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.thromres.2025.109306_bb0035","first-page":"494","article-title":"Factor VIII half-life and clinical phenotype of severe hemophilia A","volume":"90","author":"van Dijk","year":"2005","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.thromres.2025.109306_bb0040","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3390\/diagnostics13030420","article-title":"Acquired hemophilia a: an update on the etiopathogenesis, diagnosis, and treatment","volume":"13","author":"Zanon","year":"2023","journal-title":"Diagnostics"},{"issue":"Suppl. 3","key":"10.1016\/j.thromres.2025.109306_bb0045","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2516.2008.01708.x","article-title":"Back to the future: a recent history of haemophilia treatment","volume":"14","author":"Mannucci","year":"2008","journal-title":"Haemophilia"},{"issue":"15","key":"10.1016\/j.thromres.2025.109306_bb0050","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJM198704093161505","article-title":"Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions","volume":"316","author":"Schimpf","year":"1987","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.thromres.2025.109306_bb0055","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJM198910263211702","article-title":"Absence of anti-human immunodeficiency virus types 1 and 2 seroconversion after the treatment of hemophilia A or von Willebrand\u2019s disease with pasteurized factor VIII concentrate","volume":"321","author":"Schimpf","year":"1989","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.thromres.2025.109306_bb0060","first-page":"840","article-title":"Recombinant clotting factors","volume":"99","author":"Pipe","year":"2008","journal-title":"Thromb. Haemost."},{"issue":"9","key":"10.1016\/j.thromres.2025.109306_bb0065","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3390\/ph16091195","article-title":"Damoctocog alfa pegol for hemophilia A prophylaxis: an Italian multicenter survey","volume":"16","author":"Zanon","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"11","key":"10.1016\/j.thromres.2025.109306_bb0070","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1182\/blood.V106.11.3221.3221","article-title":"Role of radiotherapy in hemophiliac pseudotumors: an experience from India","volume":"106","author":"Mahapatra","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2025.109306_bb0075","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/JBM.S103796","article-title":"Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?","volume":"8","author":"Lieuw","year":"2017","journal-title":"Journal of Blood Medicine"},{"issue":"4","key":"10.1016\/j.thromres.2025.109306_bb0080","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/hae.13221","article-title":"Haemophilia patients\u2019 unmet needs and their expectations of the new extended half-life factor concentrates","volume":"23","author":"von Mackensen","year":"2017","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.thromres.2025.109306_bb0085","first-page":"575","article-title":"Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy","volume":"12","author":"Rocino","year":"2014","journal-title":"Blood Transfus."},{"issue":"4","key":"10.1016\/j.thromres.2025.109306_bb0090","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/jcm6040039","article-title":"Outcome of clinical trials with new extended half-life FVIII\/IX concentrates","volume":"6","author":"Mancuso","year":"2017","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.thromres.2025.109306_bb0095","first-page":"691","article-title":"Modern treatment of haemophilia","volume":"73","author":"B erntorp","year":"1995","journal-title":"Bull. World Health Organ."},{"issue":"3","key":"10.1016\/j.thromres.2025.109306_bb0100","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/hae.15001","article-title":"Classification of recombinant factor VIII products and implications for clinical practice: a systematic literature review","volume":"30","author":"Ay","year":"2024","journal-title":"Haemophilia"},{"issue":"S6","key":"10.1016\/j.thromres.2025.109306_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.thromres.2025.109306_bb0110","doi-asserted-by":"crossref","DOI":"10.2196\/resprot.6558","article-title":"Development of a web-accessible population pharmacokinetic service\u2014hemophilia (WAPPS-Hemo): study protocol","volume":"5","author":"Iorio","year":"2016","journal-title":"JMIR Research Protocols"},{"issue":"1","key":"10.1016\/j.thromres.2025.109306_bb0115","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1182\/asheducation-2017.1.595","article-title":"Using pharmacokinetics to individualize hemophilia therapy","volume":"2017","author":"Iorio","year":"2017","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"issue":"4","key":"10.1016\/j.thromres.2025.109306_bb0120","doi-asserted-by":"crossref","DOI":"10.2196\/resprot.6559","article-title":"Data analysis protocol for the development and evaluation of population pharmacokinetic models for incorporation into the web-accessible population pharmacokinetic service\u2014hemophilia (WAPPS-Hemo)","volume":"5","author":"McEneny-King","year":"2016","journal-title":"JMIR Research Protocols"},{"issue":"7","key":"10.1016\/j.thromres.2025.109306_bb0125","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/jth.14153","article-title":"Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH","volume":"16","author":"Ragni","year":"2018","journal-title":"J. Thromb. Haemost."},{"issue":"Suppl. 4","key":"10.1016\/j.thromres.2025.109306_bb0130","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/hae.12405","article-title":"Changing paradigm of prophylaxis with longer acting factor concentrates","volume":"20","author":"Carcao","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109306_bb0135","series-title":"Bioequivalence of Recombinant Factor VIII Products: A Position Paper from the Italian Association of Hemophilia Centers: Bioequivalence of rFVIII Concentrates","author":"Zanon","year":"2023"},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2025.109306_bb0140","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1111\/jth.12929","article-title":"Half-life extended factor VIII for the treatment of hemophilia A","volume":"13","author":"Tiede","year":"2015","journal-title":"J. Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.thromres.2025.109306_bb0145","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/j.1365-2516.2009.02077.x","article-title":"Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens","volume":"15","author":"Berntorp","year":"2009","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.thromres.2025.109306_bb0150","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/hae.13834","article-title":"Real-life experience in switching to new extended half-life products at European haemophilia centres","volume":"25","author":"Peyvandi","year":"2019","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.thromres.2025.109306_bb0155","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1160\/TH07-12-0717","article-title":"Safety of bevacizumab in mild haemophilia B","volume":"99","author":"Lambert","year":"2008","journal-title":"Thromb. Haemost."},{"issue":"9","key":"10.1016\/j.thromres.2025.109306_bb0160","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1007\/s12325-021-01853-0","article-title":"Matching-adjusted indirect comparison of efficacy and consumption of rVIII-SingleChain versus two recombinant FVIII products used for prophylactic treatment of adults\/adolescents with severe haemophilia A","volume":"38","author":"Bonanad","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.thromres.2025.109306_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2019.00261","article-title":"Status of recombinant factor VIII concentrate treatment for hemophilia A in Italy: characteristics and clinical benefits","volume":"6","author":"Schiavoni","year":"2019","journal-title":"Front. Med."},{"key":"10.1016\/j.thromres.2025.109306_bb0170","author":"Takeda Manufacturing Austria AG"},{"issue":"3","key":"10.1016\/j.thromres.2025.109306_bb0175","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/hae.13438","article-title":"Defining extended half-life rFVIII\u2014a critical review of the evidence","volume":"24","author":"Mahlangu","year":"2018","journal-title":"Haemophilia"},{"issue":"10276","key":"10.1016\/j.thromres.2025.109306_bb0180","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0140-6736(20)32722-7","article-title":"The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing","volume":"397","author":"Mancuso","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2025.109306_bb0185","doi-asserted-by":"crossref","unstructured":"Chhabra, Amita; Spurden, Deanb; Fogarty, Patrick F.c; Tortella, Bartholomew J.c; Rubinstein, Emilya; Harris, Simonb; Pleil, Andreas M.d,*; Mellor, Jennifere; de Courcy, Jonathane; Alvir, Jos\u00e9a. Real-world outcomes associated with standard half-life and extended half-life factor replacement products for treatment of haemophilia A and B. Blood Coagulation & Fibrinolysis 31(3):p 186\u2013192, April 2020. | DOI: https:\/\/doi.org\/10.1097\/MBC.0000000000000885.","DOI":"10.1097\/MBC.0000000000000885"},{"key":"10.1016\/j.thromres.2025.109306_bb0190","doi-asserted-by":"crossref","unstructured":"Roggeri, Daniela Paola, Ezio Zanon, Chiara Biasoli, and Alessandro Roggeri. \u201cExtended half-life RFVIII for the treatment of hemophilia A: drugs consumption and patients' perspective.\u201d Farmeconomia. Health Economics and Therapeutic Pathways 21, no. 1 (June 10, 2020). doi:https:\/\/doi.org\/10.7175\/fe.v21i1.1472.","DOI":"10.7175\/fe.v21i1.1472"},{"issue":"5","key":"10.1016\/j.thromres.2025.109306_bb0195","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/bjh.13360","article-title":"Role of enhanced half-life factor VIII and IX in the treatment of haemophilia","volume":"169","author":"Mahdi","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.thromres.2025.109306_bb0200","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s40271-019-00374-x","article-title":"Exploring the impact of infusion frequency in hemophilia A: exit interviews with patients participating in BAY 94-9027 extension studies (PROTECT VIII)","volume":"12","author":"Wells","year":"2019","journal-title":"Patient"},{"issue":"3","key":"10.1016\/j.thromres.2025.109306_bb0205","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A","volume":"123","author":"Mahlangu","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.thromres.2025.109306_bb0210","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","article-title":"Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A","volume":"126","author":"Konkle","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.thromres.2025.109306_bb0215","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1160\/TH16-06-0444","article-title":"Clinical evaluation of glycoPEGylated recombinant FVIII: efficacy and safety in severe haemophilia a","volume":"117","author":"Giangrande","year":"2017","journal-title":"Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2025.109306_bb0220","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.13597","article-title":"Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII","volume":"15","author":"Reding","year":"2017","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2025.109306_bb0225","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/hae.13803","article-title":"How patients view extended half-life products: impressions from real-world experience (the HOPE study)","volume":"25","author":"Khair","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109306_bb0230","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2147\/PPA.S196103","article-title":"Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII","volume":"13","author":"Kearney","year":"2019","journal-title":"Patient Prefer. Adherence"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825000556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825000556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T05:50:03Z","timestamp":1745560203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384825000556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":46,"alternative-id":["S0049384825000556"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109306","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FVIII half-life products: A real-world experience","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109306","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109306"}}